Cargando…

Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy

PURPOSE: To evaluate whether cystatin C in serum (sCyC) and urine (uCyC) can predict early acute kidney injury (AKI) in a mixed heterogeneous intensive care unit (ICU), and also whether these biomarkers can predict the need for renal replacement therapy (RRT). METHODS: Multicenter prospective observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Royakkers, Annick A. N. M., Korevaar, Johanna C., van Suijlen, Jeroen D. E., Hofstra, Lieuwe S., Kuiper, Michael A., Spronk, Peter E., Schultz, Marcus J., Bouman, Catherine S. C.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042095/
https://www.ncbi.nlm.nih.gov/pubmed/21153403
http://dx.doi.org/10.1007/s00134-010-2087-y
_version_ 1782198509371392000
author Royakkers, Annick A. N. M.
Korevaar, Johanna C.
van Suijlen, Jeroen D. E.
Hofstra, Lieuwe S.
Kuiper, Michael A.
Spronk, Peter E.
Schultz, Marcus J.
Bouman, Catherine S. C.
author_facet Royakkers, Annick A. N. M.
Korevaar, Johanna C.
van Suijlen, Jeroen D. E.
Hofstra, Lieuwe S.
Kuiper, Michael A.
Spronk, Peter E.
Schultz, Marcus J.
Bouman, Catherine S. C.
author_sort Royakkers, Annick A. N. M.
collection PubMed
description PURPOSE: To evaluate whether cystatin C in serum (sCyC) and urine (uCyC) can predict early acute kidney injury (AKI) in a mixed heterogeneous intensive care unit (ICU), and also whether these biomarkers can predict the need for renal replacement therapy (RRT). METHODS: Multicenter prospective observational cohort study in patients ≥18 years old and with expected ICU stay ≥72 h. The RIFLE class for AKI was calculated daily, while sCyC and uCyC were determined on days 0, 1, and alternate days until ICU discharge. Test characteristics were calculated to assess the diagnostic performance of CyC. RESULTS: One hundred fifty-one patients were studied, and three groups were defined: group 0 (N = 60), non-AKI; group 1 (N = 35), AKI after admission; and group 2 (N = 56), AKI at admission. We compared the two days prior to developing AKI from group 1 with the first two study days from group 0. On Day –2, median sCyC was significantly higher (0.93 versus 0.80 mg/L, P = 0.01), but not on Day –1 (0.98 versus 0.86 mg/L, P = 0.08). The diagnostic performance for sCyC was fair on Day –2 [area under the curve (AUC) 0.72] and poor on Day –1 (AUC 0.62). Urinary CyC had no diagnostic value on either of the two days prior to AKI (AUC <0.50). RRT was started in 14 patients with AKI; sCyC and uCyC determined on Day 0 were poor predictors for the need for RRT (AUC ≤0.66). CONCLUSIONS: In this study, sCyC and uCyC were poor biomarkers for prediction of AKI and the need for RRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-010-2087-y) contains supplementary material, which is available to authorized users.
format Text
id pubmed-3042095
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-30420952011-03-29 Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy Royakkers, Annick A. N. M. Korevaar, Johanna C. van Suijlen, Jeroen D. E. Hofstra, Lieuwe S. Kuiper, Michael A. Spronk, Peter E. Schultz, Marcus J. Bouman, Catherine S. C. Intensive Care Med Original PURPOSE: To evaluate whether cystatin C in serum (sCyC) and urine (uCyC) can predict early acute kidney injury (AKI) in a mixed heterogeneous intensive care unit (ICU), and also whether these biomarkers can predict the need for renal replacement therapy (RRT). METHODS: Multicenter prospective observational cohort study in patients ≥18 years old and with expected ICU stay ≥72 h. The RIFLE class for AKI was calculated daily, while sCyC and uCyC were determined on days 0, 1, and alternate days until ICU discharge. Test characteristics were calculated to assess the diagnostic performance of CyC. RESULTS: One hundred fifty-one patients were studied, and three groups were defined: group 0 (N = 60), non-AKI; group 1 (N = 35), AKI after admission; and group 2 (N = 56), AKI at admission. We compared the two days prior to developing AKI from group 1 with the first two study days from group 0. On Day –2, median sCyC was significantly higher (0.93 versus 0.80 mg/L, P = 0.01), but not on Day –1 (0.98 versus 0.86 mg/L, P = 0.08). The diagnostic performance for sCyC was fair on Day –2 [area under the curve (AUC) 0.72] and poor on Day –1 (AUC 0.62). Urinary CyC had no diagnostic value on either of the two days prior to AKI (AUC <0.50). RRT was started in 14 patients with AKI; sCyC and uCyC determined on Day 0 were poor predictors for the need for RRT (AUC ≤0.66). CONCLUSIONS: In this study, sCyC and uCyC were poor biomarkers for prediction of AKI and the need for RRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-010-2087-y) contains supplementary material, which is available to authorized users. Springer-Verlag 2010-12-10 2011 /pmc/articles/PMC3042095/ /pubmed/21153403 http://dx.doi.org/10.1007/s00134-010-2087-y Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original
Royakkers, Annick A. N. M.
Korevaar, Johanna C.
van Suijlen, Jeroen D. E.
Hofstra, Lieuwe S.
Kuiper, Michael A.
Spronk, Peter E.
Schultz, Marcus J.
Bouman, Catherine S. C.
Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy
title Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy
title_full Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy
title_fullStr Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy
title_full_unstemmed Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy
title_short Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy
title_sort serum and urine cystatin c are poor biomarkers for acute kidney injury and renal replacement therapy
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042095/
https://www.ncbi.nlm.nih.gov/pubmed/21153403
http://dx.doi.org/10.1007/s00134-010-2087-y
work_keys_str_mv AT royakkersannickanm serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT korevaarjohannac serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT vansuijlenjeroende serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT hofstralieuwes serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT kuipermichaela serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT spronkpetere serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT schultzmarcusj serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy
AT boumancatherinesc serumandurinecystatincarepoorbiomarkersforacutekidneyinjuryandrenalreplacementtherapy